Physician profile
Eric Caywood
NPI 1194722371
$13,044.79
in general payments reported to CMS, 2019-2025
62 companies · $252 in 2025
The $252 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,127 · 2020: $2,357 · 2021: $3,025 · 2022: $2,631 · 2023: $2,552 · 2024: $101 · 2025: $252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,536 · Education: $194 · Consulting Fee: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,536.15 |
| Education | $194.34 |
| Consulting Fee | $175.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,474.66 | 2020-2023 | Qulipta, Ubrelvy, Vraylar |
| Astrazeneca Pharmaceuticals LP | $1,343.38 | 2019-2023 | Farxiga, Breztri |
| Novo Nordisk INC | $1,148.73 | 2019-2023 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $1,022.21 | 2019-2023 | |
| Amgen INC. | $750.65 | 2019-2025 | Prolia, Repatha, Evenity |
| Allergan, INC. | $616.19 | 2019-2020 | |
| Lilly USA, LLC | $611.30 | 2019-2023 | Mounjaro, Jardiance, Zepbound |
| Astellas Pharma US INC | $569.16 | 2019-2024 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $346.30 | 2019-2024 | Xifaxan |
| Janssen Pharmaceuticals, INC | $344.68 | 2019-2023 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $338.78 | 2019-2022 | |
| Abbott Laboratories | $303.05 | 2022-2023 | Freestyle Libre 3, Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $292.33 | 2019-2023 | Spiriva Respimat, Jardiance |
| Amarin Pharma, INC. | $281.63 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $237.01 | 2020-2023 | Verquvo, Belsomra, Steglatro |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Caywood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.